These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


644 related items for PubMed ID: 15582526

  • 21. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series.
    Coterón JM, Catterick D, Castro J, Chaparro MJ, Díaz B, Fernández E, Ferrer S, Gamo FJ, Gordo M, Gut J, de las Heras L, Legac J, Marco M, Miguel J, Muñoz V, Porras E, de la Rosa JC, Ruiz JR, Sandoval E, Ventosa P, Rosenthal PJ, Fiandor JM.
    J Med Chem; 2010 Aug 26; 53(16):6129-52. PubMed ID: 20672841
    [Abstract] [Full Text] [Related]

  • 22. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease.
    Domínguez JN, López S, Charris J, Iarruso L, Lobo G, Semenov A, Olson JE, Rosenthal PJ.
    J Med Chem; 1997 Aug 15; 40(17):2726-32. PubMed ID: 9276017
    [Abstract] [Full Text] [Related]

  • 23. Structural basis for the regulation of cysteine-protease activity by a new class of protease inhibitors in Plasmodium.
    Hansen G, Heitmann A, Witt T, Li H, Jiang H, Shen X, Heussler VT, Rennenberg A, Hilgenfeld R.
    Structure; 2011 Jul 13; 19(7):919-29. PubMed ID: 21742259
    [Abstract] [Full Text] [Related]

  • 24. Centenary celebrations article: Cysteine proteases of human malaria parasites.
    Pandey KC.
    J Parasit Dis; 2011 Oct 13; 35(2):94-103. PubMed ID: 23024488
    [Abstract] [Full Text] [Related]

  • 25. Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3.
    Subramanian S, Hardt M, Choe Y, Niles RK, Johansen EB, Legac J, Gut J, Kerr ID, Craik CS, Rosenthal PJ.
    PLoS One; 2009 Oct 13; 4(4):e5156. PubMed ID: 19357776
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of Plasmodium falciparum cysteine proteases by the sugarcane cystatin CaneCPI-4.
    Melo PMS, El Chamy Maluf S, Azevedo MF, Paschoalin T, Budu A, Bagnaresi P, Henrique-Silva F, Soares-Costa A, Gazarini ML, Carmona AK.
    Parasitol Int; 2018 Apr 13; 67(2):233-236. PubMed ID: 29288140
    [Abstract] [Full Text] [Related]

  • 27. Identification and biochemical characterization of vivapains, cysteine proteases of the malaria parasite Plasmodium vivax.
    Na BK, Shenai BR, Sijwali PS, Choe Y, Pandey KC, Singh A, Craik CS, Rosenthal PJ.
    Biochem J; 2004 Mar 01; 378(Pt 2):529-38. PubMed ID: 14629194
    [Abstract] [Full Text] [Related]

  • 28. Falcipain-2 inhibitors.
    Ettari R, Bova F, Zappalà M, Grasso S, Micale N.
    Med Res Rev; 2010 Jan 01; 30(1):136-67. PubMed ID: 19526594
    [Abstract] [Full Text] [Related]

  • 29. BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria.
    Li X, Chen H, Jeong JJ, Chishti AH.
    Mol Biochem Parasitol; 2007 Sep 01; 155(1):26-32. PubMed ID: 17583361
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
    Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC.
    Antimicrob Agents Chemother; 2007 Mar 01; 51(3):1064-70. PubMed ID: 17178799
    [Abstract] [Full Text] [Related]

  • 31. Targeting Cysteine Proteases from Plasmodium falciparum: A General Overview, Rational Drug Design and Computational Approaches for Drug Discovery.
    Bekono BD, Ntie-Kang F, Owono Owono LC, Megnassan E.
    Curr Drug Targets; 2018 Mar 01; 19(5):501-526. PubMed ID: 28003005
    [Abstract] [Full Text] [Related]

  • 32. Blocking effect of a biotinylated protease inhibitor on the egress of Plasmodium falciparum merozoites from infected red blood cells.
    Gelhaus C, Vicik R, Schirmeister T, Leippe M.
    Biol Chem; 2005 May 01; 386(5):499-502. PubMed ID: 15927894
    [Abstract] [Full Text] [Related]

  • 33. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.
    Desai PV, Patny A, Gut J, Rosenthal PJ, Tekwani B, Srivastava A, Avery M.
    J Med Chem; 2006 Mar 09; 49(5):1576-84. PubMed ID: 16509575
    [Abstract] [Full Text] [Related]

  • 34. Antimalarial activities of novel synthetic cysteine protease inhibitors.
    Lee BJ, Singh A, Chiang P, Kemp SJ, Goldman EA, Weinhouse MI, Vlasuk GP, Rosenthal PJ.
    Antimicrob Agents Chemother; 2003 Dec 09; 47(12):3810-4. PubMed ID: 14638488
    [Abstract] [Full Text] [Related]

  • 35. Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate.
    Gelhaus C, Vicik R, Hilgenfeld R, Schmidt CL, Leippe M, Schirmeister T.
    Biol Chem; 2004 May 09; 385(5):435-8. PubMed ID: 15196005
    [Abstract] [Full Text] [Related]

  • 36. Selection of cysteine protease inhibitor-resistant malaria parasites is accompanied by amplification of falcipain genes and alteration in inhibitor transport.
    Singh A, Rosenthal PJ.
    J Biol Chem; 2004 Aug 20; 279(34):35236-41. PubMed ID: 15192087
    [Abstract] [Full Text] [Related]

  • 37. Stage-specific antimalarial activity of cysteine protease inhibitors.
    Shenai BR, Semenov AV, Rosenthal PJ.
    Biol Chem; 2002 May 20; 383(5):843-7. PubMed ID: 12108550
    [Abstract] [Full Text] [Related]

  • 38. Falcipains, Plasmodium falciparum cysteine proteases as key drug targets against malaria.
    Teixeira C, Gomes JR, Gomes P.
    Curr Med Chem; 2011 May 20; 18(10):1555-72. PubMed ID: 21428877
    [Abstract] [Full Text] [Related]

  • 39. Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum.
    Singh A, Rosenthal PJ.
    Antimicrob Agents Chemother; 2001 Mar 20; 45(3):949-51. PubMed ID: 11181388
    [Abstract] [Full Text] [Related]

  • 40. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
    Naughton JA, Nasizadeh S, Bell A.
    Mol Biochem Parasitol; 2010 Oct 20; 173(2):81-7. PubMed ID: 20478341
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 33.